Sansom, DM;
Walker, LSK;
(2019)
Dimers Aren't Forever: CD80 Breaks up with PD-L1.
Immunity
, 51
(6)
pp. 972-974.
10.1016/j.immuni.2019.11.011.
Preview |
Text
Sansom combined acceptedPDF.pdf - Accepted Version Download (1MB) | Preview |
Abstract
Targeting the CTLA-4 and PD-1 “checkpoints” is an effective treatment for a number of cancers. In this issue of Immunity, Hui et al. reveal that interaction between a CTLA-4 ligand, CD80, and its counterpart in the PD-1 pathway, PD-L1, affects both PD-1 and CTLA-4 function, raising new questions about the biological effects of using checkpoint inhibitors alone and in combination.
| Type: | Article |
|---|---|
| Title: | Dimers Aren't Forever: CD80 Breaks up with PD-L1 |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.immuni.2019.11.011 |
| Publisher version: | https://doi.org/10.1016/j.immuni.2019.11.011 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10090902 |
Archive Staff Only
 |
View Item |
